Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aliaksandra Samoila

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Cancer Journal (Sudbury, Mass.)|October 18, 2016
Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer PatientsDaniel C Danila, Aliaksandra Samoila, Chintan Patel, et al.
The Journal of Applied Laboratory Medicine|July 1, 2020
Developing Quality Programs for Cell-Free DNA (cfDNA) Extraction from Peripheral BloodAliaksandra Samoila, Jose Sosa, Jessica Padilla, et al.
British Journal of Cancer|February 10, 2017
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR<sup>+</sup>, HER2<sup>-</sup> advanced breast cancer: results from BOLERO-2Mary Ellen Moynahan, David Chen, Wei He, et al.
JAMA Oncology|August 18, 2016
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical TrialSarat Chandarlapaty, David Chen, Wei He, et al.
Oncotarget|December 30, 2017
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutationParisa Momtaz, James J Harding, Charlotte Ariyan, et al.
JCO Precision Oncology|April 10, 2018
Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with <i>EWSR1</i> fusion-positive sarcomasNeerav N Shukla, Juber A Patel, Heather Magnan, et al.
JCO Precision Oncology|July 12, 2021
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket StudyLillian M Smyth, Jonathan B Reichel, Jiabin Tang, et al.
Nature Medicine|August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activationEmiliano Cocco, Alison M Schram, Amanda Kulick, et al.
Nature|January 25, 2019
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluidAlexandra M Miller, Ronak H Shah, Elena I Pentsova, et al.
Cancer Discovery|December 7, 2019
Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast CancerLillian M Smyth, Sarina A Piha-Paul, Helen H Won, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cancer Journal (Sudbury, Mass.)|October 18, 2016
Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer PatientsDaniel C Danila, Aliaksandra Samoila, Chintan Patel, et al.
The Journal of Applied Laboratory Medicine|July 1, 2020
Developing Quality Programs for Cell-Free DNA (cfDNA) Extraction from Peripheral BloodAliaksandra Samoila, Jose Sosa, Jessica Padilla, et al.
British Journal of Cancer|February 10, 2017
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR<sup>+</sup>, HER2<sup>-</sup> advanced breast cancer: results from BOLERO-2Mary Ellen Moynahan, David Chen, Wei He, et al.
JAMA Oncology|August 18, 2016
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical TrialSarat Chandarlapaty, David Chen, Wei He, et al.
Oncotarget|December 30, 2017
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutationParisa Momtaz, James J Harding, Charlotte Ariyan, et al.
JCO Precision Oncology|April 10, 2018
Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with <i>EWSR1</i> fusion-positive sarcomasNeerav N Shukla, Juber A Patel, Heather Magnan, et al.
JCO Precision Oncology|July 12, 2021
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket StudyLillian M Smyth, Jonathan B Reichel, Jiabin Tang, et al.
Nature Medicine|August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activationEmiliano Cocco, Alison M Schram, Amanda Kulick, et al.
Nature|January 25, 2019
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluidAlexandra M Miller, Ronak H Shah, Elena I Pentsova, et al.
Cancer Discovery|December 7, 2019
Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast CancerLillian M Smyth, Sarina A Piha-Paul, Helen H Won, et al.
Pageof 2